SINGAPORE—Increased caffeine intake may reduce fatty liver in individuals with non-alcoholic fatty liver disease (NAFLD), according to researchers from Duke-NUS Graduate Medical School and Duke University School of Medicine.
Worldwide, 70% of people diagnosed with diabetes and obesity have NAFLD, the major cause of fatty liver not due to excessive alcohol consumption. This condition is rising in Singapore and in the U.S., 30% of people have this condition. The only current treatment for NAFLD is diet and exercise.
Using cell culture and mouse models, the study authors—led by Paul Yen, M.D., associate professor and research fellow, and Rohit Sinha, Ph.D of the Duke-NUS Graduate Medical School’s Cardiovascular and Metabolic Disorders Program in Singapore—observed that caffeine stimulates the metabolization of lipids stored in liver cells and decreased the fatty liver of mice that were fed a high-fat diet. These findings suggest that consuming the equivalent caffeine intake of four cups of coffee or tea a day may be beneficial in preventing and protecting against the progression of NAFLD in humans.
“This is the first detailed study of the mechanism for caffeine action on lipids in liver and the results are very interesting," Yen said. “Coffee and tea are so commonly consumed and the notion that they may be therapeutic, especially since they have a reputation for being 'bad' for health, is especially enlightening."
The team said this research could lead to the development of caffeine-like drugs that do not have the usual side effects related to caffeine, but retain its therapeutic effects on the liver. It could serve as a starting point for studies on the full benefits of caffeine and related therapeutics in humans.
Previous research has shown that drinking two or more cups of coffee a day, while taking Tamoxafin—the widely-used cancer drug—may help decrease the risk of breast cancer recurring in patients.
The findings of the study will be published in the September issue of the journal Hepatology.